CNS Platform BIORCHESTRA's brain-targeting RNAi nanomedicine platform (BTRiN) and recognition from Merck create a compelling CNS-focused partnership proposition, including licensing or co-development deals with pharma.

Partnership Track Record Active collaborations with SK Biopharm and iProgen demonstrate a proven ability to execute external R&D programs, enabling business development conversations around expanded joint development, milestone-based licensing, or strategic alliances.

Leadership and Funding New leadership in business development and ongoing financing signals readiness to scale partnerships, negotiate larger deals, and invest in joint development and commercial planning.

Global Footprint Global presence in Cambridge, MA and Korea positions BIORCHESTRA to support cross-border R&D, regulatory strategy, and potential global manufacturing or clinical development collaborations.

Clinical Momentum Steady clinical progress and notable in-vivo outcomes bolster credibility for early-access programs, co-development, or CRO and consulting engagements aimed at accelerating timelines.